Related Experiment Video
Updated: May 3, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
An obese body habitus does not preclude a minimally invasive partial nephrectomy
Christopher Reynolds1, Michael Hannon, Kathleen Lehman
1Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
Minimally invasive partial nephrectomy (MIPN) is feasible and safe for obese patients with renal cell carcinoma (RCC). Obesity class did not impact surgical outcomes, with RENAL nephrometry score being the only predictor of complications.
Area of Science:
- Urology
- Surgical Oncology
- Nephrology
Background:
- Partial nephrectomy (PN) is standard for renal cell carcinoma (RCC) when feasible.
- Outcomes of minimally invasive partial nephrectomy (MIPN) in obese patients require further definition.
- This study evaluates MIPN feasibility in obesity classes I-III compared to lower BMI.
Purpose of the Study:
- To assess the safety and efficacy of MIPN in patients with varying degrees of obesity.
- To compare surgical outcomes of MIPN between obese and non-obese patient cohorts.
- To identify factors associated with perioperative complications in MIPN.
Main Methods:
- Retrospective review of 184 patients undergoing laparoscopic or robotic MIPN.
- Patients stratified into four BMI groups: <30, 30-35 (Class I), 35-40 (Class II), >40 (Class III).
- Analysis of perioperative and pathologic outcomes, including operative time, ischemia duration, EBL, and complications.
Main Results:
- No significant difference in perioperative or pathologic outcomes was observed between obese and non-obese patients.
- Obesity class or degree of obesity did not correlate with adverse surgical outcomes.
- Higher RENAL nephrometry score (≥8) was the only significant predictor of complications (HR 5.1).
Conclusions:
- Obesity classification is not associated with adverse outcomes after MIPN for RCC.
- MIPN is a viable option for obese patients with RCC.
- RENAL nephrometry score is a critical factor in predicting complications, not patient BMI.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Drug Dosing: Obese Patients
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Kidney Transplant I: Introduction
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

